Research Roundup


smart light bulb on orange background

Debbie Rigby takes a look at the latest in research news related to pharmacy

Management of Rhinosinusitis

Rhinosinusitis is characterised by symptomatic inflammation of the nasal cavity and paranasal sinuses that decreases quality of life. The treatment of acute rhinosinusitis primarily involves symptomatic control with intranasal corticosteroids and nasal saline irrigation. Antibiotics should be reserved for the patients who are believed to have bacterial rhinosinusitis. Treating chronic rhinosinusitis involves using intranasal corticosteroids and irrigation, systemic corticosteroids, and potentially systemic antibiotics.

Curr Opin Allergy Clin Immunol. 2016;16(4):383-389. 

 

Non-steroidal anti-inflammatory drugs and risk of heart failure

A large nested case-control study has confirmed that current use of any NSAID (use in preceding 14 days) is associated with a 19% increase of risk of hospital admission for heart failure. The risk of admission for heart failure increased for traditional NSAIDs (diclofenac, ibuprofen, indomethacin, ketorolac, naproxen, and piroxicam) and two COX 2 inhibitors (etoricoxib and rofecoxib). Risk of heart failure doubled for diclofenac, etoricoxib, indomethacin, piroxicam, and rofecoxib used at very high doses. However, there was no evidence that celecoxib increased the risk of admission for heart failure at commonly used doses.

BMJ 2016;354:i4857.

Editorial
Medscape comment

 

Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone

A large 26 week study of 11,693 patients aged 12 years and older with moderate-to-severe asthma has demonstrated that treatment with budesonide–eformoterol is associated with a lower risk of asthma exacerbations than budesonide and a similar risk of serious asthma-related events.

N Engl J Med 2016; 375:850-860.

Commentary

 

Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma

A RCT of children with asthma, aged 4 to 11 years, has shown that salmeterol in a fixed-dose combination with fluticasone is associated with the risk of a serious asthma-related event that was similar to the risk with fluticasone alone. Children included in the trial, which was conducted over 6 months, used daily asthma medications and had a history of asthma exacerbations in the previous year.

N Engl J Med 2016; 375:840-849.

Editorial

 

 

Previous UK media backs community pharmacy after 'reckless' cuts
Next Forum: rural pharmacist shortage

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.